Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
Two nucleotides joined by a pyrophosphate. Enzymes reduce it to NADH. CD38 and PARP consume it. Extra NAD is not a catecholamine stimulant.
Flushing anecdotes do not make NAD a vasoactive drug class. The chemistry is cofactor redox.
NAD accepts a hydride and becomes NADH in dehydrogenase reactions. Sirtuins and PARP use NAD as a substrate and release nicotinamide. CD38 also consumes it.
Mitochondria, DNA repair, and immune cells all draw on the same pool. Adding NAD outside the cell does not tell you which of those sinks changes. Half-life after a dose was not extracted.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Flush and energy · unverified
IV and injectable NAD threads center on flushing, chest warmth, and a nonspecific energy claim. The chemistry is a redox cofactor. The posts do not show which enzyme sink changed.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.